腺苷、利多卡因与镁离子(ALM)复苏液对实验性创伤性脑损伤具有保护作用
本研究在大鼠侧方液体冲击致中度TBI模型(2.57 atm)中,比较ALM复苏液(3% NaCl+腺苷+利多卡因+Mg2+)与盐水对照的效果。伤后15分钟静脉给予单次0.7 mL/kg弹丸,60分钟后以0.5 mL/kg/h维持3小时。ALM组死亡率0%,盐水对照组25%;ALM显著增加心功能与皮层脑血流约三倍,降低全身炎症因子、脑损伤标志物,减轻凝血功能障碍并维持纤维蛋白原水平。生存时间与血浆神经元特异性烯醇化酶及180分钟脑血流显著相关。
要点
- 大鼠中度TBI后,ALM组死亡率0%,盐水对照组25%(无硬膜下探头亚组)。
- ALM弹丸后60分钟,皮层脑血流较盐水对照增加约三倍,并显著改善心功能。
- ALM维持3小时后降低全身促炎因子(IL-1β、TNF-α、RANTES),升高脑组织抗炎因子(IL-10、IL-4)。
- ALM降低脑损伤标志物(神经元特异性烯醇化酶、Syndecan-1、HMGB-1)并减轻凝血功能障碍、增加血小板聚集。
- 生存时间与血浆神经元特异性烯醇化酶(p=0.001)及180分钟脑血流(p=0.009)显著相关。
适用人群与场景
- 麻醉、机械通气的雄性Sprague-Dawley大鼠(449±5 g),采用侧方液体冲击损伤(2.57 atm)诱导的中度TBI模型。
- 每组16只,其中每组8只植入硬膜下探头测量脑血流。
处置流程与药物剂量
- 伤后15分钟静脉注射单次3% NaCl±ALM弹丸(0.7 mL/kg)。
- 弹丸后60分钟(Phase 1结束),给予0.9% NaCl±ALM稳定滴注(0.5 mL/kg/h)持续3小时(Phase 2)。
研究设计与关键结果
- 研究类型:动物实验(大鼠液体冲击TBI模型),随机分为假手术组、无治疗组、盐水对照组和ALM治疗组,每组n=16。
- 死亡率:盐水对照组25%,ALM组0%(无硬膜下探头亚组)。
- 弹丸后60分钟,ALM较盐水对照显著增加心功能和皮层脑血流(约三倍),并减轻全身炎症。
- 滴注3小时后,ALM改善左心室功能、维持更高脑血流、降低全身促炎因子(IL-1β、TNF-α、RANTES)、升高脑组织抗炎因子(IL-10、IL-4)、降低脑损伤标志物(神经元特异性烯醇化酶、Syndecan-1、HMGB-1)、减轻凝血功能障碍、增加血小板聚集并维持基线纤维蛋白原水平。
- 盐水对照组表现为脑、心、肺和血液促炎状态、低凝及神经源性右心扩大。
- 生存时间与血浆神经元特异性烯醇化酶(p=0.001)及180分钟脑血流(p=0.009)显著相关;脑血流与脑抗炎因子相关(p=0.001-0.034)。
证据类型、等级与局限
- 证据类型:动物实验(大鼠模型)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,ALM复苏液在中度TBI后通过减少凝血功能障碍、炎症和血小板功能障碍,提高生存率并防止早期继发性损伤。
- 原文未据此给出临床推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Currently, no drug therapy prevents secondary injury progression after traumatic brain injury (TBI). Our aim was to investigate the effects of small-volume intravenous adenosine, lidocaine, and Mg (ALM) resuscitation fluid after moderate TBI in a rat fluid-percussion injury model.
METHODS: Anesthetized, mechanically ventilated male Sprague-Dawley rats (449 ± 5 g) were randomly assigned to one of four groups: (1) sham (craniotomy without TBI), (2) no-treatment, (3) saline-control, or (4) ALM therapy groups (all n = 16). A subdural probe was implanted in eight animals per group to measure cerebral blood flow. Fifteen minutes after moderate TBI was induced with lateral fluid percussion injury (2.57 atm), a single 3% NaCl ± ALM bolus (0.7 mL/kg) was injected intravenously, and after 60 minutes (Phase 1), 0.9% NaCl ± ALM stabilization "drip" (0.5 mL/kg per hour) was administered for 3 hours (Phase 2).
RESULTS: Mortality (without subdural brain probe) was 25% (saline controls) and 0% (ALM). Sixty minutes after bolus, ALM significantly increased cardiac function, cortical blood flow (CBF; approximately threefold) and blunted systemic inflammation compared to saline controls. Three hours after infusion drip, ALM improved left ventricular function, supported higher CBF, decreased proinflammatory cytokines systemically (IL-1β, tumor necrosis factor α, and regulated on activation, normal T cell expressed and secreted [RANTES]), increased anti-inflammatory cytokines in brain tissue (IL-10, IL-4), lowered brain injury markers (neuron-specific enolase, Syndecan-1, HMGB-1), reduced coagulopathy, increased platelet aggregation, and maintained baseline fibrinogen levels. Saline-controls were proinflammatory (brain, heart, lung, and blood) and hypocoagulable with neurogenic enlargement of the right side of the heart. Survival time significantly correlated with plasma neuron-specific enolase (p = 0.001) and CBF at 180 minutes (p = 0.009), and CBF correlated with brain anti-inflammatory cytokines (p = 0.001-0.034).
CONCLUSION: After moderate TBI, ALM resuscitation fluid increased survival and protected against early secondary injury by reducing coagulopathy, inflammation, and platelet dysfunction.
参考来源
- Letson HL, Dobson GP. Adenosine, lidocaine, and Mg2+ (ALM) resuscitation fluid protects against experimental traumatic brain injury. J Trauma Acute Care Surg. 2018. PMID: 29554045. doi:10.1097/TA.0000000000001874
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。